4H7W

Crystal Structure of Human C16orf57

Summary for 4H7W

• Entry DOI: 10.2210/pdb4h7w/pdb
• Descriptor: UPF0406 protein C16orf57, GLYCEROL, CHLORIDE ION, ... (4 entities in total)
• Functional Keywords: 2h phosphoesterase, unknown function
• Biological source: Homo sapiens (human)
• Cellular location: Nucleus: Q9BQ65
• Total number of polymer chains: 1
• Total formula weight: 22686.42

Authors

Hilcenko, C.,Simpson, P.J.,Warren, A.J. (deposition date: 2012-09-21, release date: 2013-02-06, Last modification date: 2024-02-28)

Primary citation

Hilcenko, C.,Simpson, P.J.,Finch, A.J.,Bowler, F.R.,Churcher, M.J.,Jin, L.,Packman, L.C.,Shlien, A.,Campbell, P.,Kirwan, M.,Dokal, I.,Warren, A.J.
Aberrant 3' oligoadenylation of spliceosomal U6 small nuclear RNA in poikiloderma with neutropenia.
Blood, 121:1028-1038, 2013

PubMed Abstract: The recessive disorder poikiloderma with neutropenia (PN) is caused by mutations in the C16orf57 gene that encodes the highly conserved USB1 protein. Here, we present the 1.1 Å resolution crystal structure of human USB1, defining it as a member of the LigT-like superfamily of 2H phosphoesterases. We show that human USB1 is a distributive 3'-5' exoribonuclease that posttranscriptionally removes uridine and adenosine nucleosides from the 3' end of spliceosomal U6 small nuclear RNA (snRNA), directly catalyzing terminal 2', 3' cyclic phosphate formation. USB1 measures the appropriate length of the U6 oligo(U) tail by reading the position of a key adenine nucleotide (A102) and pausing 5 uridine residues downstream.We show that the 3' ends of U6 snRNA in PN patient lymphoblasts are elongated and unexpectedly carry nontemplated 3' oligo(A) tails that are characteristic of nuclear RNA surveillance targets. Thus, our study reveals a novel quality control pathway in which posttranscriptional 3'-end processing by USB1 protects U6 snRNA from targeting and destruction by the nuclear exosome. Our data implicate aberrant oligoadenylation of U6 snRNA in the pathogenesis of the leukemia predisposition disorder PN.

PubMed: 23190533
DOI: 10.1182/blood-2012-10-461491

Experimental method

X-RAY DIFFRACTION (1.1 Å)